PEOPLE ON THE MOVE
Rich Pharmaceuticals
Rich Pharmaceuticals, a biopharma company developing drugs for blood diseases, has announced Richard Salvador will join its board. Salvador is an alumnus of both big pharma and small biotech start-ups.
At Hoffman La Roche, he served as VP, International Pre-clinical development, and was Deputy to the President of International R&D. He is currently Chairman of Angiogenex and serves on the board of several other biopharma companies.
Rich Pharmaceuticals’ oncology pipeline includes candidates for Acute Myelocytic Leukemia (AML), Myelodysplastic Syndromes (MDS) and Hodgkin's Lymphoma. Its lead product, RP-323, is a phorbol ester which induces differentiation and apoptosis in cells,activates protein kinase C, and modulates the activity of several downstream cell signaling pathways.
